BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37327539)

  • 1. Patterns of cervical cancer screening follow-up in the era of prolonged screening intervals.
    Kulkarni A; Chen L; Gockley A; Khoury-Collado F; Hou J; Clair CST; Melamed A; Hershman DL; Wright JD
    Gynecol Oncol; 2023 Aug; 175():53-59. PubMed ID: 37327539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of cervical cancer screening among Medicaid beneficiaries.
    Dillon J; Chen L; Melamed A; St Clair CM; Hou JY; Khoury-Collado F; Gockley A; Accordino M; Hershman DL; Wright JD
    BJOG; 2022 Jun; 129(7):1104-1111. PubMed ID: 34882962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
    JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women-A cohort study.
    Westre B; Giske A; Guttormsen H; Wergeland Sørbye S; Skjeldestad FE
    PLoS One; 2019; 14(11):e0221546. PubMed ID: 31689301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
    BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
    Elfström KM; Smelov V; Johansson AL; Eklund C; Nauclér P; Arnheim-Dahlström L; Dillner J
    BMJ; 2014 Jan; 348():g130. PubMed ID: 24435414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of abnormal cervical and vaginal cytology among women over age 65 years living with human immunodeficiency virus.
    Stewart KA; Allen SM; Chesnokova AE; Syed F; Levison JE
    Am J Obstet Gynecol; 2020 May; 222(5):486.e1-486.e10. PubMed ID: 31678094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
    Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
    J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
    Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
    BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.
    Uijterwaal MH; Polman NJ; Van Kemenade FJ; Van Den Haselkamp S; Witte BI; Rijkaart D; Berkhof J; Snijders PJ; Meijer CJ
    Cancer Prev Res (Phila); 2015 Jun; 8(6):502-8. PubMed ID: 25776933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
    Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
    PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical management.
    Cuzick J; Myers O; Hunt WC; Saslow D; Castle PE; Kinney W; Waxman A; Robertson M; Wheeler CM;
    Int J Cancer; 2015 Jun; 136(12):2854-63. PubMed ID: 25447979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society.
    Fontham ETH; Wolf AMD; Church TR; Etzioni R; Flowers CR; Herzig A; Guerra CE; Oeffinger KC; Shih YT; Walter LC; Kim JJ; Andrews KS; DeSantis CE; Fedewa SA; Manassaram-Baptiste D; Saslow D; Wender RC; Smith RA
    CA Cancer J Clin; 2020 Sep; 70(5):321-346. PubMed ID: 32729638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women.
    Del Mistro A; Frayle H; Ferro A; Callegaro S; Del Sole A; Stomeo A; Cirillo E; Fedato C; Pagni S; Barzon L; Zorzi M;
    J Med Screen; 2014 Mar; 21(1):30-7. PubMed ID: 24488593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV testing with cytology triage for cervical cancer screening in routine practice.
    Louvanto K; Chevarie-Davis M; Ramanakumar AV; Franco EL; Ferenczy A
    Am J Obstet Gynecol; 2014 May; 210(5):474.e1-7. PubMed ID: 24373948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.